Please select the eligibility criteria that correspond to the clinical trial below.
Title: Dexamethasone for Cardiac Surgery Trial
Brief Summary: This is a multicenter, randomized, double-blind trial, comparing clinical outcomes after the administration of high-dose dexamethasone versus placebo in patients undergoing heart surgery with the use of cardiopulmonary bypass. The primary endpoint is the occurrence of major complications (including all-cause mortality, myocardial infarction, stroke, renal failure, and prolonged mechanical ventilation) in the first 30 days after surgery.


Options:
A: Inclusion Criteria:

* All types of cardiac surgery in which cardiopulmonary bypass is used

Exclusion Criteria:

* Age under 18 years
* Life-expectancy \< 6 months
* Emergency operations
* Re-operations within the same admission
B: Inclusion Criteria:

* Age 18-64
* ISS \>15
* Infusion can be started within 24 hrs of arrival to FMLH (time of injury irrelevant)
* Admitted to Inpatient hospital trauma service (not Ortho/Plastics/Neurosurgery etc)

Exclusion Criteria:

* Age \<18 or \>64
* History of adverse reaction to ketamine therapy
* Chronic opioid therapy defined as \> 3 weeks of \>30mg oral morphine equivalents per day
* Current substance abuse with opioids including prescription and/or heroin
* Intubation on arrival or need for urgent intubation on arrival
* GCS \<13, significant traumatic brain injury, or suspicion of elevated intracranial pressure resulting in the patient's inability to communicate
* History of psychosis
* Active delirium
* Glaucoma
* Ischemic heart disease defined as active acute coronary syndrome
* Severe, poorly controlled hypertension (SBP \>200) on more than two readings
* Aortic Injury requiring HR and BP control
* Concurrent use of monoamine oxidase inhibitors (MAOIs)
* Pregnancy
* Prisoners
* Inability to start investigational drug infusion within 24 hours of arrival
C: Inclusion Criteria:

1. 18 plus years
2. A native Japanese speaking ability
3. Possibility to contact patients with injury in 240 hours, and dosing in oral use
4. Physical and metal status to possible understands scope and contents in the trial and gets informed consent

Exclusion Criteria:

1. Clearly irretrievable acute brain parenchyma damage and subdural or subarachnoidal bleeding detected by computed tomography and/or magnetic resonance imaging
2. Cognitive impairment: Mini Mental State Examination \< 24
3. Heavy drinker or 100IU/L ≦ γGTP in administration
4. Heavy smoker (over 40 cigarettes per day)
5. History and current suspicion in diagnosis of psychosis and bipolar I disorder
6. Suspicion in diagnosis of alcoholic, substance-related disorder and eating disorder
7. Existence of marked serious symptoms such as suicidal ideation, self-harm behavior, dissociation, status of need rapidly psychiatric treatment
8. Use of anti-epilepsy drug, lithium, ethyl icosapentate and anti-coagulant drug (for example, aspirin, warfarin, etc) within 3 month at regular intervals
9. Use of polyunsaturated fatty acid supplement within 3 month at regular intervals
10. Habit of eating fish over 4 times per week
D: Inclusion Criteria:

* victims of motor vehicle accidents
* signed informed consent

Exclusion Criteria:

* pregnancy
* traumatic brain injury
* psychiatry disorders
* active cancerous conditions
* adrenal diseases
* medical treatment by estrogens, anti-depressants, melatonin, pain control.
* substance abuse
* hospitalization due to the trauma
* contra indication to hydrocortisone treatment
* over 6 hours from time of injury

Answer: A